Welcome to Dilaforette

Introduction

Frimarke

Dilaforette is a drug development company developing a heparan sulphate mimetic, sevuparin, a proprietary drug derived from heparin. Sevuparin is an innovative, disease-modifying polysaccharide drug, with extensive world-wide IP protection.

Sevuparin is intended to be used as an anti-adhesive therapy and has therefore been designed to retain the anti-adhesives effects of heparin, while reducing the anti-coagulant properties. Sevuparin, with demonstrated strong anti-adhesive effects, has the potential to be of clinical use in several therapeutic conditions. Dilaforette is currently developing sevuparin for acute vaso-occlusive crises in sickle cell disease as the initial indication as well as for malaria.

Background

Dilaforette, a Swedish drug development company, founded by leading scientists in malaria from Karolinska Institute as well as leading experts in the field of heparin and drug development from Uppsala University and the Swedish pharmaceutical industry together with Karolinska Innovation AB.

-> Read more under About us

  • News

    • Dilaforette receives Orphan Drug Designation in the U.S. for sevuparin in Sickle-Cell Disease

      2015-03-20 07:36:19 STOCKHOLM, SWEDEN - March 20, 2015. Dilaforette AB today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for sevuparin (DF02) for the treatment of patients with sickle-cell disease (SCD). The company is currently in the final stage of study preparation for a Phase II study in SCD with sevuparin and aim to start recruitment of patients during the first half of 2015. Sevuparin is an innovative, proprietary polysaccharide drug, which has the potential to restore

    • Dilaforette Announces Co-Development Agreement with Ergomed for Sickle-Cell Disease Treatment

      2015-02-19 08:16:38 STOCKHOLM, LONDON – 19 February 2015: Ergomed plc (LSE: ERGO or ‘Ergomed’) and Dilaforette AB (‘Dilaforette’) today announced that they have entered into a co-development agreement for the Phase II clinical development of sevuparin in patients with Sickle-Cell Disease (SCD) experiencing acute Vaso-Occlusive Crisis (VOC). Dilaforette is part of the Karolinska Development AB (STO: KDEV or ‘Karolinska Development’) portfolio. Under the terms of the agreement, Ergomed has been appointed as the clinical development organisation to conduct Dilaforette’s multicentre, multinational, randomized Phase

    • Dilaforette receives positive COMP opinion on Orphan Drug Designation in the EU for sevuparin in Sickle-Cell Disease

      2015-01-19 14:21:43 STOCKHOLM, SWEDEN - January 19, 2015. Dilaforette AB today announced that it has received positive opinion from the Committee for Orphan Medicinal Products (COMP) on orphan drug designation in the EU for sevuparin (DF02) for the treatment of patients with sickle-cell disease (SCD). The opinion will now be forwarded to the European Commission for final ratification. The company is currently in final stage of study preparation for a Phase II study in SCD with sevuparin and aim to start recruitment

    • Dilaforette presented clinical results in malaria at the American Society of Tropical Medicine and Hygiene (ASTMH) meeting, in New Orleans, USA.

      2014-11-28 12:03:14 Dilaforette presented results from the exploratory Phase I/II clinical trial in uncomplicated malaria with its candidate drug sevuparin at the American Society of Tropical Medicine and Hygiene (ASTMH) meeting, in New Orleans, USA, held 2-6 November 2014.   In this study, important early anti-adhesive effects with a potential to improve the outcome for patients with severe malaria were seen with sevuparin in adult patients with uncomplicated falciparum malaria as adjunct treatment. Sevuparin was found to be safe and well tolerated. For more

    • Dilaforette presents results from exploratory Phase I/II clinical trial in uncomplicated malaria

      2014-05-30 10:06:35 STOCKHOLM, SWEDEN – May 30, 2014. Today, Dilaforette AB announced the results from an exploratory Phase I/II clinical trial in malaria with its candidate drug sevuparin. Sevuparin was studied in adult patients with uncomplicated falciparum malaria as adjunct treatment and was found to be safe and well tolerated. The study results indicates important early anti-adhesive effects with a potential to improve the outcome for patients with severe malaria, even though the primary efficacy endpoint was not met. Karolinska Development owns